Skip to main content

John Strickler

Professor of Medicine
Medicine, Medical Oncology
Dept of Medicine, BOX_2823, Durham, NC 27710

Selected Grants


Dabrafenib + trametinib in patients w/rare BRAF V600E mutated solid tumor (CDRB436IIC01)

Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2023 - 2029

Study drug QTX3034 for patients with KRAS G12D solid tumors (QTX3034-001)

Clinical TrialPrincipal Investigator · Awarded by Quanta Therapeutics, Inc. · 2024 - 2029

Study drug RMC-9805 for patients with KRAS G12D solid tumors (RMC-9805-001)

Clinical TrialPrincipal Investigator · Awarded by Revolution Medicines, Inc · 2024 - 2029

Dabrafenib + trametinib in patients w/rare BRAF V600E mutated solid tumor (CDRB436IIC01)

Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2023 - 2029

Study drug QTX3034 for patients with KRAS G12D solid tumors (QTX3034-001)

Clinical TrialPrincipal Investigator · Awarded by Quanta Therapeutics, Inc. · 2024 - 2029

Study drug RMC-9805 for patients with KRAS G12D solid tumors (RMC-9805-001)

Clinical TrialPrincipal Investigator · Awarded by Revolution Medicines, Inc · 2024 - 2029

Perioperative dostarlimab vs standard of care for resectable colon cancer (219606)

Clinical TrialPrincipal Investigator · Awarded by GlaxoSmithKline · 2023 - 2028

BGB-A317-LBL-007-201

Clinical TrialPrincipal Investigator · Awarded by BeiGene USA, Inc. · 2023 - 2028

ABBV-400 for Advanced Solid Tumors

Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2023 - 2028

NCCN/Lilly Grant to Optimize Biomarker Driven Therapy in Lung and Thyroid Cancers

ResearchPrincipal Investigator · Awarded by National Comprehensive Cancer Network · 2024 - 2027

A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications

Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2023 - 2026

Daiichi Sankyo - Safety and Efficacy of U3-1402 in Subjects with Advanced or Metastatic Colorectal Cancer

Clinical TrialPrincipal Investigator · Awarded by Daiichi Sankyo Inc · 2020 - 2025

SGNTUC-024 Tucatinib plus trastuzumab and oxaliplatin-based chemotherapy for HER2+ gastrointestinal cancers

Clinical TrialPrincipal Investigator · Awarded by Seattle Genetics, Inc · 2020 - 2025

A Phase 1A/B Study To Evaluate The Safety And Tolerability Of ETC-1922159 In Advanced Solid Tumours

Clinical TrialPrincipal Investigator · Awarded by Experimental Drug Development Centre · 2020 - 2025

COLOMATE: COlorectal Cancer Liquid BiOpsy Screening Protocol for Molecularly Assigned ThErapy

Clinical TrialPrincipal Investigator · Awarded by Academic and Community Cancer Research United · 2019 - 2025

Mountaineer-Phase ll (ACCRU)

Clinical TrialPrincipal Investigator · Awarded by Seattle Genetics, Inc · 2019 - 2024

Investigational drug GB1275 in combo with standard therapy for certain metastatic GI cancers

Clinical TrialPrincipal Investigator · Awarded by Gossamer Bio · 2020 - 2023

Implementing Evidence-Based Interventions to Enhance Equity in Oncology Genomic Testing

ResearchCo Investigator · Awarded by V Foundation for Cancer Research · 2022 - 2023

Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer

Clinical TrialCo Investigator · Awarded by National Institutes of Health · 2014 - 2023

Partnership to Support the Duke Molecular Tumor Board Program

Inst. Training Prgm or CMEPrincipal Investigator · Awarded by Bayer Healthcare Pharmaceuticals Inc · 2020 - 2022

Mountaineer-Phase ll (ACCRU)

Clinical TrialPrincipal Investigator · Awarded by Academic and Community Cancer Research United · 2017 - 2022

Phase Ib study of Atezolizumab in combination with Bevacizumab in solid tumor patients

Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2017 - 2022

An open label multicenter dose escalation and expansion phase IB study to evaluste the safety pharmacokinetics and therapeutic activity

Clinical TrialPrincipal Investigator · Awarded by F. Hoffmann-La Roche Ltd · 2016 - 2020

A Phase 1, multicenter, open-label, dose-escalation study of SNF-2FF in patients with advanced solid tumors

Clinical TrialPrincipal Investigator · Awarded by Seattle Genetics, Inc · 2017 - 2020

External Relationships


  • AbbVie Pharmaceuticals
  • Agenus
  • Astellas Pharma Inc.
  • AstraZeneca
  • Bayer
  • AbbVie Pharmaceuticals
  • Agenus
  • Astellas Pharma Inc.
  • AstraZeneca
  • Bayer
  • BeiGene
  • Daiichi Sankyo Co., Ltd
  • Eli Lilly & Co.
  • Genentech, Inc (Roche Holding)
  • GlaxoSmithKline
  • Jazz Pharmaceuticals
  • Johnson and Johnson
  • Merck Sharp & Dohme Inc., One Merck Drive, Whitehouse Station, NJ 08889-0100.
  • Natera
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Sanofi
  • Taiho
  • Takeda Oncology
  • Triumvira Immunologics
  • Xilio Therapeutics

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.